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53 and PTEN are two major tumor 
suppressors that keep cell growth in 
check (1). Loss of tumor suppressor 
activity through deletion or mutation con-
tributes to many human tumors.
Lloyd Trotman was lured from Zürich, 
Switzerland, to do his postdoctoral work 
with Pier Paolo Pandolfi   at Sloan-Kettering 
in New York City. There, he and his col-
leagues found that loss of one allele of 
PTEN triggers cancer, 
whereas biallelic loss 
exposes cells to growth 
suppression by a se-
nescence pathway me-
diated by p53, fi  ndings 
that contradict the 
classic two-hit model 
of tumor suppression 
(2, 3). He also showed 
that PTEN shuttles be-
tween the cytoplasm 
and nucleus (4)—odd behavior for a 
protein thought to act mainly at the 
plasma membrane.
Now directing his own research group 
at Cold Spring Harbor, Trotman is work-
ing to understand the relevance of PTEN 
nuclear localization to PTEN function 
and cancer and to grasp the importance 
of the p53 senescence pathway in human 
cancer. We called him to discuss how 
he  tackles big questions and dogmatic 
concepts in biology.
FONDNESS FOR FUNDAMENTALS
When did you decide you were 
interested in science?
It was always clear that I liked certain 
sciences quite a bit—I was really drawn 
to physics and chemistry because I 
wanted to be able to understand things 
on the most basic, fundamental level. 
On the other hand, I have to say that I 
also was always fl  irting with the social 
sciences. Even after I had entered Zürich 
University to study biochemistry, I took 
a break once for a year to study art history 
and theory of science in a different 
country. I am married to an art historian. 
The funny thing is that the one thing that 
I really never wanted to do after high 
school was biology. I was drawn back to 
it much later.
How did you select Urs Greber’s lab 
for your graduate work?
At the end of my university studies, I didn’t 
really know what I wanted to do most. I’d 
been working with very basic biochemical 
questions in biology, like functional pep-
tide and protein design, but I wasn’t really 
sure if that fi  eld was making substantial 
progress. So I took some time and worked 
in a Drosophila lab, where I was exposed 
to the power of genetics.
Later on, there was an opening in Urs’s 
lab there in Zürich, where they were using 
viruses to tackle cell biological questions. 
Viruses have devel-
oped together with 
their host cells for 
tens of thousands of 
years, so you can 
study the interaction 
of a virus with the 
cell and ask it to re-
veal the cell’s secrets 
that it is exploiting 
to its own ends. I 
liked this approach 
of studying some-
thing fundamental in 
a peculiar way.
CHALLENGING DOGMA
You made a big switch to studying cancer 
biology in your postdoctoral work.
Our work with viruses was touching on 
many aspects of cell biology, and one of 
them was nuclear architecture. I was 
trying to tackle questions of how adeno-
virus gets its DNA through the nuclear 
pore complex, and one of the steps had to 
do with a nuclear structure called the 
PML body, which Pier Paolo Pandolfi 
had discovered in a completely different 
context: leukemia. I was fascinated by the 
fact that the PML protein is essential for 
forming a nuclear structure; if you don’t 
have the protein, this whole structure falls 
apart, and this structure is clearly involved 
in cancer. After talking to him, it was clear 
I wanted to work with Pier Paolo.
When I got to Pandolfi  ’s lab, I origi-
nally wanted to work on PML, but nobody 
was working with PTEN at the time, and 
he convinced me very quickly that I 
should really look at PTEN. Our fi  rst 
problem was that there were so many 
mouse models that we could have been 
using at the time. We fi  nally decided to 
look at PTEN gene dosage in cancer. It 
paid off big time.
Pandolfi   also has this willingness to 
think of the fundamental things that we 
know about cancer in totally different 
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ways and to toss them overboard if new 
ideas make more sense. I could take my 
background in transport biology, nuclear 
import, and nuclear biology into what we 
were studying to do something that is 
totally nonmainstream. For example, I 
wanted know why there is PTEN in the 
nucleus when it’s supposed to act at the 
membrane. Is that at all important? How 
does it get in and what is it doing there? 
After my second week, I had these ideas, 
but it was only four tough years later that 
we actually got clear answers to those 
original questions.
What has been the biggest challenge in 
your work so far?
The biggest conceptual challenge is con-
nected to one of the biggest discoveries 
that came out of our lab at the time: the 
senescence principle, that the complete 
loss of PTEN causes senescence. At the 
time, that concept was just impossible; 
loss of both alleles of a tumor suppressor 
was supposed to cause cancer.
Amazingly, I’d had the result for some 
time, that complete loss of PTEN doesn’t 
allow a cell to proliferate. I had the job 
of creating PTEN-null mouse embryonic 
fi  broblasts in the Cre/Lox system using 
adenovirus to deliver Cre, but I just could 
not get cells to grow after adding the virus. 
We transferred the task to a technician, 
who got the same result with a different 
virus, but since he was also crossing PTEN-
nulls with p53-nulls, he clearly saw that 
embryonic fi  broblasts that have neither 
protein would proliferate very well.
Pier Paolo had this idea—could it be 
that p53 triggers senescence when you 
lose PTEN? To me, that was going too far. 
I just felt it was too much. But I went back 
to my adenovirus experiment and included 
all the right controls, testing if a PTEN-
null cell actually had a growth disadvan-
tage. Everything all of a sudden started to 
make sense. It was clear that if they only 
lose one copy of PTEN, cells proliferate 
a lot more, but if they lose both, they 
become senescent. It was a lesson in 
how hard it is to overcome a preconceived 
notion that is totally entrenched, that less 
tumor suppressor will always give you 
more of a proliferative advantage.
On the other hand, our biggest technical 
challenge had to do with understanding 
a mutation in PTEN that was not in a 
place that was expected to affect PTEN 
function. We had clearly seen that PTEN 
is modifi  ed at the mutation site by some-
thing that’s added onto it. I spent four 
years trying to identify what is added (it 
turned out to be ubiquitin), but during this 
whole time it wasn’t really clear if what 
we were looking at was something that 
really plays a role in cells. The only thing 
that kept us going was that somebody 
had identifi  ed a patient family that had a 
mutation on our major target site, and that 
having this mutation there would give you 
a disease. We fi  nally got some histology 
slides from these patients, and it was clear 
that the mutant PTEN really had a prob-
lem in going into the nucleus.
OF MICE AND POSTDOCS
It sounds like you have had to put in a lot 
of time in the mouse room for this work.
Yes. That’s something that Pandolfi   in-
sisted upon. We did everything with the 
mice ourselves, and it was key to be in 
intimate contact with your colony so you 
knew exactly what was going on. That 
was essential for realizing some impor-
tant details that could have been easily 
missed. That’s what 
I tell my students 
and postdocs now, 
“Anything that you 
want to cross, you 
want to follow up. 
There’s going to be 
minimal help from 
a technician, because 
I want you to be there 
with these mice, and 
I want you to realize 
if there’s a problem with something like 
the Mendelian ratio at which they’re 
born or if they look different at birth—
whatever it is, I want you to be on top of it.”
What questions are you focusing 
on now in your own lab at Cold 
Spring Harbor?
One thing we are looking at in my lab is 
what PTEN does in the nucleus. It could 
be that it’s a protective mechanism to have 
PTEN there, because in the nucleus PTEN 
is not degraded as easily as in the cyto-
plasm. We also want to understand whether 
the known (or novel) targets of PTEN are 
in the nucleus in a relevant fraction, or if 
they shuttle between the nucleus and other 
compartments. We will need mouse models 
to ask if any aberration in this regulation 
will actually cause cancer, and we will 
work with patient samples to look at its 
importance for human cancer. There’s 
also another whole layer involved in the 
senescence pathway in human tumors. 
We think the PTEN haploinsuffi  ciency 
and senescence paradigms could form the 
basis of understanding this cancer from 
the bottom up.
I also think we shouldn’t forget that 
you cannot solve the big problem by 
trying to solve the big problem. What 
you have to do is try to solve a small, 
tractable problem that you believe to be 
extremely relevant.
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Cells that completely lack PTEN do not form 
tumors unless they can avoid senescence 
mediated by Akt (green) and p53.
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